Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer ( PROC ) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

7 days ago

COPENHAGEN, Denmark, Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ( Nasdaq: ASND ) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer ( PROC ) treated with TransCon IL-2 β/γ in combination with ...

Ticker	Sentiment	Impact
ASND	Neutral	7 %